Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KPI-121 1% dosed · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| KPI-121 1% Ophthalmic Suspension dosed BID | DRUG | - |
| Vehicle of KPI-121 Ophthalmic Suspension dosed BID | DRUG | - |
KPI-121 1% dosed is an investigational small molecule being developed for the treatment of post-surgical ocular inflammation and pain. It is intended to address inflammation and pain following eye surgery. The drug is currently in clinical development and has not been approved by regulatory authorities.
KPI-121 1% dosed is being developed by KALA BIO, Inc., a biopharmaceutical company. KALA BIO, Inc. is publicly traded under the ticker symbol KALA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for post-surgical ocular inflammation and pain.
KPI-121 1% dosed is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 3 trial has been completed, and the drug remains under investigation for post-surgical ocular inflammation and pain.
KPI-121 1% dosed has one completed Phase 3 clinical trial with the identifier NCT02793817. The trial, titled "Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain," enrolled 520 participants in the United States. The study was randomized and double-blind, though it was uncontrolled.
KPI-121 1% dosed is not FDA approved. It is an investigational drug currently in clinical development for post-surgical ocular inflammation and pain. A Phase 3 clinical trial has been completed, but the drug has not received regulatory approval. It remains under investigation for safety and efficacy.